



ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

9th February 2019

Metropolitan Stock Exchange of India Ltd
4th Floor, Vibgyor Towers, Plot No. C 62,
G Block, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E),
MUMBAI – 400 098

Dear Sir,

Sub: Unaudited Financial Results for the quarter ended 31st December 2018
Ref: Circular No.MSE/LIST/5903/2018 dated 1.1.2018
Symbol: AFDIL, Series: BE

We refer to our letter dated 1st February 2019 informing you of our Board Meeting that is scheduled today. The Meeting of the Board of Directors commenced at 12.30 pm and concluded at 2.30 pm. The Board approved unaudited financial results for the quarter ended 31st December 2018.

We are enclosing a copy of the Unaudited Financial Results for the quarter ended 31st December 2018, which were taken on record at the meeting of the Directors of the Company held today at Bangalore and the Limited Review Report, for your information.

Please take the above information on record.

Thanking you,

Yours faithfully,
Anglo-French Drugs & Industries Ltd.

Abhay Kanoria
Chairman & Managing Director

Encl: A/a

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2018

(Rs in Lacs, except No of equity shares & Earning per share)

PARTICULARS	3 months ended (31/12/2018) (Un-Audited)	3 months ended (30/09/2018) (Un-Audited)	3 months ended (31/12/2017) (Un-Audited)	9 months ended (31/12/2018) (Un-Audited)	9 months ended (31/12/2017) (Un-	Year ended (31/03/2018) (Audited)
1. Income						
(a) Revenue from operations	3323	2986	3211	10018	8026	11141
(b) Other Income	4	50	6	79	38	95
Total Income	3327	3036	3217	10097	8064	11236
2. Expenses						
(a) Cost of Material Consumed	917	765	1606	2879	3022	4113
(b) Purchase of Stock in Trade	704	487	616	1958	1662	2312
(c) Changes in Inventories of Finished goods, work in progress & Stock in Trade	19	1	(184)	163	146	(138)
(d) Employee Benefits Expenses	579	585	630	1761	1784	2386
(e) Finance costs	171	165	109	498	301	429
(f) Depreciation and Amortisation Expense	45	45	38	135	134	179
(g) Other Expenses	914	987	695	2727	2236	3243
Total Expenses	3349	3035	3510	10121	9285	12524
3. Profit(+)/Loss(-) before Tax (1-2)	(22)	1	(293)	(24)	(1221)	(1288)
4. Tax Expenses						
i) Current Tax	0	(1)	0	0	0	0
ii) Deferred tax	0	0	(1)	0	(1)	(167)
5. Profit(+)/Loss(-) for the period (3-4)	(22)	2	(292)	(24)	(1220)	(1121)
6. Other Comprehensive Income						
(i) Items that will not be reclassified to profit & Loss	7	4	(1)	15	(14)	17
(ii) Income tax on items that will not be reclassified to profit or loss	0		(1)	0	(1)	(1)
Total Other Comprehensive Income	7	4	(2)	15	(15)	16
7. Total Comprehensive Income (5+6)	(15)	6	(294)	(9)	(1235)	(1105)
8. Paid up equity share capital (Face value of Rs. 10 each)	11625000	11625000	11625000	11625000	11625000	11625000
9. Earnings/(Loss) Per Share (Face value of Rs. 10 each)						
a) Basic	(1.84)	0.17	(25.12)	(2.02)	(104.95)	(96.43)
b) Diluted	(1.84)	0.17	(25.12)	(2.02)	(104.95)	(96.43)

Notes:

- These financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- The Company has adopted Ind AS 115 in respect of Right of Return from distributor point of view. Under the new standard, revenue has not been recognized for goods expected to be returned and a liability has been recognized for expected refunds to customers. Corresponding cost of sales are decreased and recovery right asset is created. Application of this standard resulted into reduction in profit amounting to Rs. 9.01 lakhs. Prior period information has not been restated.
- The Company has no reportable segments other than Pharmaceuticals division as per Ind AS.
- Financial results were approved at the meeting of the Board of Directors held on 09-02-2019.
- The figures in respect of previous period have been regrouped/restated/recast wherever necessary.

Place: Bengaluru
Date: 09-02-2019

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

Abhay Kanoria
ABHAY KANORIA
CHAIRMAN & MANAGING DIRECTOR

LIMITED REVIEW REPORT

*Review Report To The Board of Directors of
Anglo-French Drugs & Industries Limited,
41, 3rd Cross, V Block, Rajajinagar,
Bangalore – 560 010.*

We have reviewed the accompanying statement of standalone unaudited financial results of **Anglo-French Drugs & Industries Limited** ("the Company"), for the quarter and nine months ended December 31, 2018 ("the Statement") being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5th 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date: 09-02-2019



For KAMG & ASSOCIATES
Chartered Accountants
Firm Registration No. 311027E


S Ganesh
(Partner)

Membership No. 232115